191 related articles for article (PubMed ID: 30697958)
1. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders.
Dharnidharka VR; Ruzinova MB; Chen CC; Parameswaran P; O'Gorman H; Goss CW; Gu H; Storch GA; Wylie K
Cancer Med; 2019 Mar; 8(3):1013-1023. PubMed ID: 30697958
[TBL] [Abstract][Full Text] [Related]
2. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
Riddler SA; Breinig MC; McKnight JL
Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879
[TBL] [Abstract][Full Text] [Related]
3. Simian virus 40 in posttransplant lymphoproliferative disorders.
Vilchez RA; Jauregui MP; Hsi ED; Novoa-Takara L; Chang CC
Hum Pathol; 2006 Sep; 37(9):1130-6. PubMed ID: 16938517
[TBL] [Abstract][Full Text] [Related]
4. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
5. In situ hybridization for Epstein-Barr virus NotI repeats in posttransplant lymphoproliferative disorder.
Montone KT; Friedman H; Hodinka RL; Hicks DG; Kant JA; Tomaszewski JE
Mod Pathol; 1992 May; 5(3):292-302. PubMed ID: 1323104
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
[TBL] [Abstract][Full Text] [Related]
7. Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus.
Lones MA; Shintaku IP; Weiss LM; Thung SN; Nichols WS; Geller SA
Hum Pathol; 1997 May; 28(5):533-9. PubMed ID: 9158700
[TBL] [Abstract][Full Text] [Related]
8. Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.
Maloney EM; Busque VA; Hui ST; Toh J; Fernandez-Vina M; Krams SM; Esquivel CO; Martinez OM
JCI Insight; 2020 Mar; 5(6):. PubMed ID: 32213705
[TBL] [Abstract][Full Text] [Related]
9. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
10. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.
Limaye AP; Huang ML; Atienza EE; Ferrenberg JM; Corey L
J Clin Microbiol; 1999 Apr; 37(4):1113-6. PubMed ID: 10074534
[TBL] [Abstract][Full Text] [Related]
11. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders.
Craig FE; Johnson LR; Harvey SA; Nalesnik MA; Luo JH; Bhattacharya SD; Swerdlow SH
Diagn Mol Pathol; 2007 Sep; 16(3):158-68. PubMed ID: 17721324
[TBL] [Abstract][Full Text] [Related]
13. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
14. Characteristic pattern of chromosomal imbalances in posttransplantation lymphoproliferative disorders: correlation with histopathological subcategories and EBV status.
Poirel HA; Bernheim A; Schneider A; Meddeb M; Choquet S; Leblond V; Charlotte F; Davi F; Canioni D; Macintyre E; Mamzer-Bruneel MF; Hirsch I; Hermine O; Martin A; Cornillet-Lefebvre P; Patey M; Toupance O; Kémény JL; Deteix P; Raphaël M
Transplantation; 2005 Jul; 80(2):176-84. PubMed ID: 16041261
[TBL] [Abstract][Full Text] [Related]
15. Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders.
Smir BN; Hauke RJ; Bierman PJ; Gross TG; d'Amore F; Anderson JR; Greiner TC
Lab Invest; 1996 Oct; 75(4):575-88. PubMed ID: 8874388
[TBL] [Abstract][Full Text] [Related]
16. The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.
Luskin MR; Heil DS; Tan KS; Choi S; Stadtmauer EA; Schuster SJ; Porter DL; Vonderheide RH; Bagg A; Heitjan DF; Tsai DE; Reshef R
Am J Transplant; 2015 Oct; 15(10):2665-73. PubMed ID: 25988622
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations.
Greiner TC; Abou-Elella AA; Smir BN; Orazi A; Hinrichs S; Anderson J; Gross T; Bierman P; Hauke R
Leuk Lymphoma; 2000 Aug; 38(5-6):563-76. PubMed ID: 10953978
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
Capello D; Berra E; Cerri M; Gaidano G
Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
[TBL] [Abstract][Full Text] [Related]
19. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
[TBL] [Abstract][Full Text] [Related]
20. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
Kuno M; Ito A; Maeshima AM; Taniguchi H; Tanaka T; Inamoto Y; Kurosawa S; Kim SW; Fukuda T
Int J Hematol; 2020 Aug; 112(2):193-199. PubMed ID: 32472530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
